Chai Discovery, a San Francisco-based AI drug discovery company whose platform is used by Eli Lilly, Pfizer, and Novartis, is hiring a Scientist for Protein Design to work on-site with its science tea…
Chai Discovery, a San Francisco-based company building AI models for biochemical structure and interaction, posted an internship listing despite stating it does not offer internships, inviting interes…
Chai Discovery, a San Francisco-based biotech startup, released Chai-3, a generative AI model for molecular design that doubles the success rate of its predecessor in creating therapeutic antibodies, …
Most AI strategies fail not because of design or technology but because employees do not believe in their leaders, according to an analysis citing BlackBerry CEO John Chen's turnaround and Gallup's St…
Freehand, a San Francisco startup, closed a $75 million Series B on July 29 to expand its autonomous AI agents that handle supply-chain spending decisions for Fortune 500 companies including Meta, Uni…
Freehand, a startup whose AI agents manage supply-chain procurement for Unilever, Pfizer, and Meta, has raised $75 million in a round co-led by Battery Ventures and NewRoad Capital Partners. The compa…
Deena Mousa, a program officer at Coefficient Giving, argues in a guest article that curing all diseases in our lifetime requires not only AI superintelligence but also ingenious government policy to …
Power companies in states like Georgia and Pennsylvania are considering using eminent domain to seize private land for transmission lines powering AI data centers, according to University of Dayton le…
More than 10,000 oncologists and drug developers gave a standing ovation in early June for Revolution Medicine's daraxonrasib, which nearly doubled survival in pancreatic cancer, highlighting U.S. lea…
Brand tracking startup Tracksuit has acquired Hall, a Sydney-based startup that measures how brands appear in AI assistant responses, adding AI-monitoring capability to its existing business of survey…
Chai Discovery Inc. has raised $400 million in Series C funding, nearly tripling its valuation to $3.8 billion, as the AI drug discovery company signs licensing agreements with Pfizer Inc., Eli Lilly …
Chai Discovery raised $400 million in a Series C round led by Index Ventures, tripling its valuation to $3.8 billion in seven months as the AI drug discovery startup's generative models are deployed a…
OpenAI researcher Miles Wang is in advanced talks to launch an AI drug discovery startup at a $2 billion valuation, with Lightspeed Venture Partners reportedly leading a $200 million round, according …
Chai Discovery has raised $400 million in a Series C round at a $3.8 billion valuation, tripling its valuation in seven months. The OpenAI-backed drug discovery startup, founded in 2024, builds AI mod…
OpenAI-backed Chai Discovery closed a $400 million funding round at a $3.8 billion valuation on July 14, tripling its price tag in seven months. The Index Ventures-led round positions the company as A…
Anduril founder Palmer Luckey warned that US universities are falling behind China's by failing to teach engineers how to build, handing China a lead in technical talent. He argued that American schoo…
Eli Lilly invested $40 million in Absci, a generative AI drug company, to develop ABS-201, an injectable antibody for baldness and endometriosis. The deal, part of a $100 million stock offering, aims …
Nasdaq CFO Sarah Youngwood says leaders must personally learn AI, not just delegate it to their teams, as the company integrates AI across its market infrastructure and finance operations. Nasdaq retu…
The UK Competition Appeal Tribunal was wrong to set aside the competition watchdog's decision against Pfizer for excessive pricing of an anti-epilepsy drug, the Court of Appeal ruled. The regulator fo…
The US Treasury is assessing whether to expand outbound investment screening to include biotechnology deals with Chinese firms, following bipartisan pressure from lawmakers. Representatives John Moole…